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1. Introduction 
The liver is a vital organ essential for life of vertebrates and other animals and plays a 
variety of metabolic functions, including glycogen storage, detoxification, plasma protein 
synthesis, the production of biochemicals for digestion and other roles. In the normal liver, 
hepatocytes physiologically renewed at very slow tempo. However, when injured by acute 
damage or drug intoxications, dormant hepatocytes re-enter the cell cycle and hepatic 
progenitor cells (HPCs) or oval cells are also thought to differentiate into hepatocytes, 
resulting in restoration of the structure and functions of the liver parenchyma (1-2): thus the 
liver has regenerative capacity. In severely overwhelmed cases, mature hepatocytes seemed 
to be blocked their proliferation activity, but HPCs are thought to be profoundly activated 
and play an important role in compensation of liver function (3, 4). When liver injury and 
inflammation occur chronically, normal liver tissue is replaced by fibrosis, scare tissue, 
diffuse necrosis and regenerative nodules (5), thus resulting in an irreversible chronic 
inflammation loss of liver function at the final stage: liver cirrhosis (LC) (6, 7, 8, 9). 
Regardless of its underlying causes, the morphologic figures and complications caused by 
LC are similar and as disease progresses, complications develop. They include portal 
hypertension, varix, ascities, hepatic encephalopathy, idiopathic peritonitis and hepatic 
coma. The classification of LC is based on the etiology, such as alcoholics, post-hepatitic, 
biliary, cardiac, metabolic, inherited and drug induced cirrhosis. Incidence of the specific 
types of liver cirrhosis is different from area to areas. Alcoholic cirrhosis is the most 
common type in North America, Western Europe and South America. Abstinence from 
alcohol would prevent the complicating liver cirrhosis (10). One-fourth of the patients with 
repeated liver injuries and three fourth of post-hepatitic cirrhosis has the history of viral 
hepatitis (hepatitis B or hepatitis C). Post-hepatitic cirrhosis induced by those viruses is the 
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most common cirrhosis found in South Eastern Asia and China including Korea, and second 
most common in America and Western Europe. In America, over 20% of patients infected 
chronically with HCV for more than 20 years were reported to develop post-hepatitic cirrhosis 
(11). Biliary cirrhosis also occurs in association with injury of the biliary system or its 
prolonged impairment, which destroys liver parenchyme with progressive fibrosis. Billary, 
cardiac, metabolic, inherited and drug induced liver cirrhosis are much less common than 
alcoholic or posthepatitic cirrhosis (12). Avoidance of causative drugs, excessive protein intake 
and anti-infectious medicine were usually used as a first choice of treatment. Overall, about 
75% of patients have progression and die within 5 years after the findings of the disease. 
Immune system is also deeply involved in the magnitude of cirrhosis. For example, in some 
instances cirrhosis can cause immune system dysfunction, leading to high susceptibility to 
infections or in other cases, autoimmune responses caused by the immunologic damage to the 
liver causing inflammation and eventually scaring and cirrhosis.  
Until now, no simple hematologic diagnostic test for the LC has been developed (13). LC is 
diagnosed by clinical findings, such as chronic liver disease, reduced platelet count, 
esophageal varix, ascitis, portal hypertension symptoms, splenomegaly and changes in 
hematologic parameters (14). For the definite diagnosis, the liver biopsy is used, although 
invasive.  
LC is the common end feature of an excessive and persistent scaring resulted from 
secondary fibrotic tissue remodeling followed by liver injuries and is regarded as 
irreversible disease. 
In the rodents, both findings that carbon tetrachloride (CCl4) treatment and bile duct ligation 
injury were reported to induce fibrogenesis (15), and spontaneous recovery from once 
established liver fibrosis (16-17), suggest that the hepatic fibrosis is a dynamic bi-directional 
event, and highlighted that the liver fibrosis is potentially reversible by antifibrotic therapy (18). 
After hepatic injury, the hepatic stellate cells (HSCs), positioned in the center of the ongoing 
fibrogenesis of liver (19), are activated to proliferate and to produce contractile elements 
such as ǂ smooth muscle actin (ǂ-sma), a major determinant of sinusoidal portal 
hypertension (27), and collagens (mainly type I and III) (21). This process is most likely 
mediated through the stimulation of cytokines, such as transforming growth factor-ǃ (TGF-
ǃ), platelet-derived growth factor (PDGF), and endothelin (ET-1) (20), that are produced in a 
synergistic fashion of paracrine and autocrine from injured hepatic cells and inflammatory 
cells. The positive feedback loops between extracellular matrix and produced cytokines may 
also play an important roles in the acceleration of fibrosis ( 22). 
Among them, TGF-ǃ1 is thought to be the most significant factor for HSCs, because it 
upregulates the expression of its receptor (23, 32), leading to raising the susceptibility to 
other mitogens such as PDGF, thrombin and angiotensin-II, etc. and eventually inducing 
proliferation of HSCs. It also accelerated the accumulation of HSCs in response to migration 
stimuli such as PDGF, vasoactive substance ET-1, and monocyte chemotatic protein (24). 
Extracellular matrix (ECM) modulates HSC functions by interacting it with PDGF, fibroblast 
growth factor (FGF), TGF-ǃ, and matrix metalloproteinases (MMPs) that present in the space 
of Disse (25). Integrins expressed on HSCs play important roles in cell-matrix interactions 
for activation of latent TGF-ǃ1 that modifies fibrogenesis.  
In contrast, basement membrane tends to suppress the proliferation activity of HSCs and 
their collagen synthesis (26). The cirrhotic liver overexpressed the ET-1 (28), a stimulant of 
nitric oxide production from HSCs and autocrine, that plays important roles for their own 
proliferation. HSCs also secrete neutrophil and monocyte chemoattractants, such as colony 
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stimulating factors (CSF), MCP-1, and IL-8 that amplify the hepatic inflammatory response 
(31). Matrix synthesis is highly dependent on TGF ǃ-1 and liver cirrhosis is closely related 
with ECM alteration in quantity and quality. Hepatic fibrosis is enhanced by synthesis of the 
neomatrix with type-1 collagen and the neomatrix degradation is inhibited by TIMPs (tissue 
inhibitor of metalloproteinases, TIMPs) (33). Thus activated HSCs are responsible for 
hepatic fibrosis. TIMP-1 inhibits apoptosis of HSCs (33) and induced promotion of 
perpetuation in hepatic fibrosis (34). 
Prevention of the unnecessary medication is important for maintaining physiological 
conditions of the liver because it is very sensitive to medicines as well as microbial infection. 
The principle of treatment in LC is to remove such potential risk factors, and to correct the 
underlying invasive causes. Currently, treatments are focused on preventing complications 
such as ascites, esophageal varix and hepatic encephalopathy etc. Detection of serological 
changes at the early stage and regular follow up studies of those features are important for 
reducing the risky liver diseases such as LC. Usually, diet, bed rest, fluid restriction and 
diuretics, paracentesis and the liver transplantation are included in the treatment of the LC 
(35-36). For the treatment of decompensated LC, orthotopic liver transplantation is regarded 
as the only definitive therapeutic option (36). Several factors such as lack of available 
donors, combined with operative risks, complications associated with rejection, usage of 
immunosuppressive agents and cost-intensiveness make this strategy available to only a 
few people (37, 41). Those problems inherent in the liver transplantation have prompted the 
search for alternative therapeutic methods for intractable liver diseases (42). Due to these 
problems, many LC patients die from life-threatening complications at relatively early age. 
Recently, along with the development of regenerative medicine, the use of pluripotent stem 
cells are proposed for recovering from the disease states as an alternative therapy (38). Fetal 
liver derived stem cells transplanted showed some improvement for conservative 
management in the end stage liver diseases (39). In clinical cell therapy, highly enriched cell 
numbers and the high repopulation potential are essential (40). 
Liver cells obtained from the post-mortem have been also used for transplantation as the 
promising alternative (43-46). The liver cell transplantation is regarded as a less invasive, 
less expensive, and can alleviate the problem of organ shortage. Although there are some 
advantages in the liver cell transplantation over the orthotopic liver transplantation, long-
term observation seems to be important for the evaluation. 
Reversal of hepatic fibrosis and cirrhosis may be achieved by resolution of liver fibrosis, an 
increase of apoptosis of activated HSCs and collagenolysis (47). In the CCl4 rat model, the 
removal of CCl4 increased the apoptosis of HSCs: 50% decrease in cell numbers at 72 hours 
post-removal. And antifibrotic therapy with NO donor decreased the HSCs number to 50% 
at 18 hours after the treatment (48). Induction of HSCs apoptosis degraded the matrix and 
recovered from the liver fibrogenetic conditions by removing the source of fibrotic 
neomatrix and TIMPs. (49-50) Biliary fibrosis was reversed after decompression of the bile 
duct ligation (51). Apoptosis of HSCs induces pro-MMP-2 activation (52) suggesting matrix 
remodeling, because MMPs specifically degrade collagens and non-collagenous substrates 
in matrix. The matrix degradation seems a pivotal initial step in the processes of liver 
fibrosis resolution. The most important event is the action of the interstitial collagenases, 
MMP-1, which cleaves the collagen-1 molecule (53). Collagenase activity resulted from the 
gap between activated MMPs to TIMPs. Increase of TIMP-1 expression occurs in parallel 
with progressive fibrosis. Sustained TIMP-1 expression means the failure in degradation of 
fibrosis and there is intrinsic link between HSC apoptosis and matrix degradation (47). This 
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suggests that the proteolysis facilitates the resolution and repair of the injured liver (54). The 
failure of degradation of fibrosis by collagenase impairs HSC apoptosis to induce the 
delaying or blocking the hepatocyte regenerative response (54). 
Recovery from the hepatic fibrosis has been reported in animal models after removal of 
CCl4, which is used for induction of acute hepatitis (55-61) and clinical patients (62-66). 
Hepatic fibrosis, induced by several toxins (57-59) or ligation of bile duct (60), was reversed 
after the removal of the causes. In human, reversal of the hepatic fibrosis was reported in 
patients with alcoholic liver disease, hemochromatosis and other liver diseases (62-64). 
Reversal of the posthepatitic cirrhosis was also noted after improvement from the hepatitis B 
infection (65). Moreover, posthepatitic cirrhosis due to hepatitis C infection responded to the 
interferon treatment. (66) 
Due to the limitation of the donor livers, the stem cell-based therapy has been suggested as a 
possible alternative therapy (67). Plasticity (trans-differentiation) and fusion activities 
inherent in stem cells are important for the development, regeneration and repair of liver 
organs (68-70, 72). The stem cells produce various humoral substances (cytokines, growth 
factors) and factors for homing or migration, also. Those characteristics of stem cells are also 
important for the therapy (71). Recently, mesenchymal stem cell (MSC) derived from 
umbilical cord (UC) is regarded as a promising form for cell therapy because of their easy 
accessibility, MSC is much primitive than other tissue sources and do not express the major 
histocompatibility complex (MHC) class II (HLA-DR) antigens (74). Previous studies have 
shown that  
UCMSC are still viable and not rejected at 4 months after xenografts, without the need for 
immune suppression, suggesting that they are a favorable cell source for transplantation 
(75-77). UCMSC are able to differentiate into adipocytes, osteocytes, chondrocytes (78,79), 
neurons (80,81), cardiomyocytes (78,82) and renal tubule epithelial cells (83) upon cultured 
in induction media. 
Initially, stem cell was isolated from bone marrow and characterized as plastic adherent 
fibroblastoid cell which has the capacity to generate some tissues (84). As study on stem cell 
has progressed, the stem cells were also found in the many other adult organs. The 
discovery of trans-differentiation potential (85) led us to use them in currently incurable or 
intractable diseases. Stem cells are used for two purposes: one is the trans-differentiation of 
stem cells into the specific cell types to replace the damaged or destroyed cells or tissues, 
and the other is the stimulation of the pre-existing native cellular repair mechanism in 
damaged organs, which may contain resident dormant stem cells. Currently, stem cell-based 
cell therapy is increasingly applied to the variety of diseases including cardiovascular issues 
(86), diabetes (87), musculoskeletal disorders (88), renal problems (89), impotence (90) and 
hepatic cirrhosis (91). Stem cells can also be used for cytokine producer. Stem and other 
cells, which are genetically engineered for the production of cytokines, are also used as a 
vehicle of cytokines for targeting injury or disease sites, such as cancer sites (92). Stem cells, 
in particular committed to hepatocytes, can also be used for screening of drug toxicity (93).  
Stem cells are classified into three, according to the differences in sources; embryonal stem 
cell (ESC), adult stem cell (ASC) and induced pluripotent stem (iPS) cell. ESC was 
developed by Thomson in Wisconsin (94). Fetal stem cells and amniotic stem cells may 
belong to this category. The differentiation potential of ESCs is great but the clinical use has 
been strictly limited due to the ethical problem and the tumorigenesis. The iPS cells were 
generated from mouse fibroblasts in 2006 by Yamanaka (95), with introduction of four 
genes; Oct 3/4, Sox2, c-Myc, and Klf 4. The potentiality of iPS cells seems appears to be 
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unlimited for clinical applications, but the bio-characterization of iPS cells has not 
established yet, although they are under intensive study. The origin of ASCs first discovered 
is bone marrows (BMSC), and then, the ASCs were discovered from the many mature 
organs (96-100). Among these, bone marrow, adipose tissues (ADSC) and umbilical cord 
blood (UCBSC) derived stem cells are currently available for cell-based clinical therapies. 
BMSCs were actively applied for the treatment of hematologic diseases, already. The 
spectrum of clinical application of BMSCs continues to expand with the time. UCBSCs are 
collected from venous blood of the cord, but the cell number collected is not great. The 
UCBSC was applied for Fanconi's anemia (101) in 1986 between siblings. UCBSC seems to 
contain the most immature form of ASCs that have few chances to contact with 
environmental antigens, immunologically immature (102). The UCBSCs do not raises any 
ethical concern at umbilical cord blood collection issues and collection can be processed 
without invasiveness for donors. The regenerative capabilities of UCBSC are similar to other 
types of ASC (103). Adipose tissue derived stem cell (ADSC) was first described by plastic 
surgeons (104). The procedure harvesting adipose tissue is a common work among plastic 
surgeons for cosmetic or regenerative purposes, although it is somewhat invasive. The 
processed lipoaspirated tissues harbor abundant multipotent stem cells, which have similar 
potential with BMSC or UCBSC (103). ADSCs are permitted for autologous cell-based 
therapy in many countries.  
The angiogenic, neurogenic and trans-differentiation potential of stem cells are the principal 
targets in stem cell based treatment (105-110). Vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (bFGF), platelet derived growth factor AB (PDGF-AB), 
transforming growth factor-ǃ (TGF-ǃ), and integrin ǃ are stem cell angiogenic factors 
(111,112). Brain-derived neurotrophic factors, and neurotrophin-4/5 (NT4/5) (113,114) are 
stem cell neurotrophic factors. Reports on the effects of stem cells for improvement of 
vascular insufficiencies (115-118) and neuropathies (119-121) are accumulating these days.  
Liver cirrhosis has been thought to be an irreversible disease. However, recent studies on 
cirrhosis of animals and humans suggest that liver cirrhosis is a potentially reversible 
disease. Stem cells, which are of anti-fibrotic and trans-differential potential, raised the 
possibility of their??? use for the treatment of liver fibrosis and cirrhosis as an alternative 
treatment replacing for liver transplantation.  
In the present study we report our pre-clinical and clinical experiences of umbilical cord 
blood derived stem cell treatment for end stage liver cirrhosis, and discuss on the stem cell 
therapy in liver cirrhosis.  
2. Materials and methods 
2.1 Preclinical study 
For the evaluation of the stem cell effect, we prepared the rat liver cirrhosis model with 
carbon tetrachloride (CCl4). Male Sprague-Dawley rats (6weeks old, 180–-200g) were used. 
The rats were grouped into 3, one control group (A) and two experimental groups, CCl4 
treated group (B) and CCl4 treatment plus stem cell treated group (C). Cirrhosis was 
induced by intraperitoneal administration of CCl4 (4:1 olive oil) at a dose of 0.1 mL/100 g 
body weights, three times a week. The same volume of olive oil only was intraperitoneally 
infused for control. For cirrhosis induction, CCl4 was infused for 8 weeks. Human umbilical 
cord blood stem cells were infused at a dose of 1x106 cells in 0.2 mL through the tail vein, 
and saline of same volume for control and CCl4 only group. Rats were sacrificed at one, two 
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and four weeks and one pathologist evaluated the pathologic changes of liver. For 
pathologic evaluation, sections of approximately 4 μm thick were made and stained with 
haematoxylin and eosin (H&E) staining for routine histology, and Masson’s trichrome (MT) 
staining for collagen. 
2.2 Clinical study  
Total 51 patients were participated in this treatment. The exclusion criteria for patient 
recruitment in stem cell treatment with liver cirrhosis were age limitation, over 70, and 
cancer. Among them, 46 patients (male 27 and 19 female) were classified as the Child-Pugh 
(CP) class C liver cirrhosis and 5 (four male and one female) were classified as the CP class 
B, finally, although they were classified as the class C from the other hospital, at the time of 
initiation. All participants are randomly involved in this treatment after reviewed the 
medical records of patients whose life expectancy were less than 6 months, evaluated by 
doctors in charge before involved in these treatments. 43 patients graduated from the 
college or upper rank school. The cause of cirrhosis was alcholic in 18 and posthepatitic in 
36. Although 17 had the heart problem, it was not definite whether cardiac problem was the 
solitary cause of the cirrhosis or not, except two. The common clinical complications for 
portal hypertension were varix (41) and ascitis (34). For all patients, the explanation was 
made on the treatments rationale and material, and informed consents were obtained. All 
patients understood the treatment and no body has the opinion on baseline studies (Table 
1). All participating patients were negative on cancer especially at baseline studies. They 
had specific conditions that could be related with liver cirrhosis and had the several 
complications induced from portal hypertension (Table 2).  
 
Imaging 
Ultrasound Exam. on Heart, Liver, Kidney 
CT on Abdomen  
Endoscopic Gastroscopy, Esophagoscopy 
Blood & Serology CBC, Serologic series 12 
Urine UA, Microscopic Examination 
Cancer Marker AFP, CEA 
Others 
VDRL, AIDS, Hepatitis B Ag/Ab, Hepatitis C AG/Ab., 
Electrolyte, C-reactive protein, ASO titer, EKG, ESR, RA factor 
Coagulation  PT (INR) 
Table 1. Base line studies. 
The human umbilical cord blood stem cells (hUCBSC) were supplied by Histostem Co. Ltd. 
(Seoul, Korea) that was permitted for clinical use from the Korean government (KFDA).  
The supplied stem cells were ABO, HLA-ABC, DR and sex matched for each patient, and 
the donor of each stem cell unit does not have any specific familial medical history. The 
stem cell markers of hUCBSCs were studies by flow cytometry. Total cell numbers that 
infused for each patient were around 1.5 x 107. hUCBSCs were infused percutaneous 
directly into liver parenchyma using needle under the ultrosonographic guide. All patients 
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were informed for usual life after one-day bed rest. Patients were followed every month 
from treatment at least for 6 times. At follow up check, patients were evaluated for 
prothrombin time, albumin, ascities and encephalopathy before and after each month from 
the stem cell therapy. Patients were evaluated for serological results, ascities and 
encephalopathy before and after each month from the stem cell therapy. The final survival 
was checked at November 30, 2010, 7 to 75 months from the initiation of the stem cell 
therapy. 
 
 
Conditions manifested 
at initial visit 
Positive Patients 
Number 
Negative 
Patients Number 
Alcohol Intoxication 18 33 
Hepatitis History 36 15 
Heart Problem 17 34 
GB Problem 0 51 
Varix 41 10 
Ascitis 34 17 
Hepatic 
encephalopathy 
19 32 
Peritonitis 1 50 
Table 2. Patient condition at presentation. 
 
Study Items Normal Value 
Normal 
Patients 
Range of Measure value 
Patients Number 
Total Protein 6.3 - 8.2 g/dL 12 39 
Albumin 
3.5 - 5.1 
g/dL 
5 
1.0 - 2.0 2.1 - 3.0 >3.1 
17 26 3 
ALP 38 – 126 13 38 
sGOT 5 – 40 IU/L 2 49 
sGPT 5 – 35 IU/L 1 50 
Total Bilirubin 
0.2 - 1.3 
mg/dL 
14 
<2mg/dL 2-3mg/dL >3mg/dL 
18 16 3 
Direct 
Bilirubin 
0 - 0.3 
mg/dL 
17 34 
PT (INR) <1.7 18 
<1.7 1.7 - 2.3 >2.3 
18 22 11 
Table 3. The results of serologic test before stem cell treatment. 
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3. Results 
3.1 Stem cells 
The flow cytometric results (Figure 1) of hUCBSCs were CD13(+), CD14(-), CD29(+), 
CD31(-), CD34(-), CD44(+), CD45(-), CD49e(+), CD54(+), CD90(+), CD106(-), AMSA(+), 
SH2(+), SH3(+), HLA-ABC(+) and HLA-DR(-).  
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Fig. 1. Flow cytometric findings of the surface markers in hUCBSCs. 
3.2 Preclinical  study 
The gross finding of the liver was examined (Figure 2) at 12 weeks after the starting the 
infusion of CCl4. Compared to the control which have normal hepatic configuration (A), the 
CCl4 infused rats (B) without stem cell treatment showed nodular surfaced distorted liver 
but CCl4 infusion with stem cell treatment rat (C) showed recovered from the distorted 
nodular liver but much distorted compared with control (A). 
The microscopic study (Figure 3), with haematoxylin and eosin (H&E) staining for routine 
histology and Masson’s trichrome (MT) staining for collagen, were done on liver section at 
1, 2 and 4 weeks after CCl4 injection for 8 weeks. The control group showed normal  
 
 
A B C 
 
Fig. 2. Gross findings of the liver at 12 weeks after initiation of the CCl4 intraperitoneal 
injections.  A is control, B is CCl4 intraperitoneal injection and C is CCl4 intraperitoneal 
injection plus hUCBSC treated rat. 
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architecture at all livers (A). At 1 week after CCl4 injection for 8 weeks, the experimental 
group showed the cirrhosis was induced in both without (B1) and with stem cell treatment 
group (C1), the fibrosis and deposition of collagen, separating liver parenchyma into large 
lobules. At 2 week after CCl4 injection for 8 weeks, there was definite difference between 
without stem cell treatment group and with stem cell group. The without stem cell 
treatment group (B2) showed increased septa composed of fibrosis and collagen. Compared 
to without stem cell group, with stem cell group (C2) showed reduced septa than first week 
after CCl4 injection for 8 weeks. At 4 week after CCl4 injection for 8 weeks, the without stem 
cell treatment group (B3) showed much increased septa composed of fibrosis and collagen 
and there is new fine septa were appeared within large lobules. In with stem cell treatment 
group (C3), the septa composed of fibrosis and collagen were reduced and the lobules are 
closely approximated each other. In these pathologic findings, experimental group without 
stem cell therapy induced the extensive fibrosis / cirrhosis and the fibrosis was progressed 
as the time passing (B). These CCl4 induced fibrosis / cirrhosis was proved by disruption of 
liver parenchyma architecture, extension of fibers, large fibrous septa formation, pseudolobe 
separation and collagen accumulation. These alterations were progressed and increased in 
fibrosis and collagen deposition with time passing. The histopathological findings 
confirmed that the cirrhosis was significantly reduced by stem cell infusion. 
 
 
 A B C 
1 
 
2 
3 
 
Fig. 3. Microscopic findings of the rat liver in control and experimental rats. A from control 
rat, B from CCl4 intraperitoneal injection only rat and C from CCl4 intraperitoneal injection 
with hUCBSC therapy rat. 1 at 9 week from CCl4 intraperitoneal injection, 2 at 10 weeks and 
3 at 12 weeks. 
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3.3 Clinical study 
The participants’ age ranged from 49 to 68 years old (mean 54.7 years). The mean age of the 
CP class C were 56.2 and class B were 48.9. After the stem cell therapy, there was no death 
within 6 months from the initiation of the stem cell therapy. There were 9 deaths from 7 
months within 12 months, 19 deaths from 13 months within 2 years, 13 deaths over 2 year 
within 3 years, 3 deaths over 3 years within 5 years. 7 are living now, from 11 to 75 months 
from stem cell therapy, and among them, two are living over 5 year. During the procedure 
(Figure 4), the bleeding from the liver was not remarkable. Clinically, ascitis was improved 
in 21 and 5 did not show any ascitis within 6 months. Among 5, 2 are alive more than 5 
years (Figure 5). In hepatic encephalopathy, all patients showed improvement in symptom. 
But there is no patient who lived more than 30 months. Serologic follow up check was done 
in all patients (Table 3 and 4). In serologic test, although there were some changes in the  
 
 
 
 
 
 
 
 
Fig. 4. Laparascopic view of percutaneous injection of the stem cells into liver. The needle is 
inserted into the nodular surfaced liver. 
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Fig. 5. CT findings from the patient who is living more than 5 years.  A is CT taken just 
before (Feb. 21, 2005) stem cell therapy and B is CT taken was after 5 months (July 23, 2005). 
The measured liver size was increased from 689.98 CC to 915.36 CC and hepatic density is 
lowered suggesting release of fibrosis. 
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results, it was impossible to get the uniform information in  trends of change. Among 39, 
those who had abnormal protein level, total protein level was normalized at 6, but among 
39, only 2 were normalized in albumin. In these 2, one had normalization of total protein 
level but one did not, meaning some difference in improvements among sub-group. 
 
Study Items Normal Value
Normal 
Patients 
Range of Measure value 
Patients Number 
Total Protein 6.3 - 8.2 18(+6) 33(-6) 
Albumin 3.5 - 5.1 7(+2) 
1.0 - 2.0 2.1 - 3.0 >3.1 
12(-5) 25(-1) 7(+4) 
ALP 38 - 126 17(+4) 34(-4) 
sGOT 
M: 17 - 59 
F: 14 - 36 
9(+7) 42(-7) 
sGPT 
M: 21 - 72 
F: 9 - 52 
12(+11) 39(-11) 
Total Bilirubin 0.2 - 1.3 16((+2) 
<2mg/dL 2-3mg/dL >3mg/dL 
21(+3) 14(-2) 0(-3) 
Direct Bilirubin 0 - 0.3 18(+1) 33(-1) 
PT (INR) <1.7 23(+5) 
<1.7 1.7 - 2.3 >2.3 
23 22 6 
Table 4. Serologic test results at post stem cell treatment 6 months. 
4. Discussion  
Most of the chronic liver injuries, regardless of their causes, progress to liver fibrosis and 
eventually result in cirrhosis that is thought to be irreversible, and the liver cirrhosis (LC) 
results in impairment of the hepatic function becoming a massive health care burden 
worldwide. LC is induced by many different causes, such as chronic viral hepatitis, toxic 
damage including alcohol, parasitic disease, inborn errors of metabolism, and non-alcoholic 
fatty liver disease etc. The cause of LC has a wide geographic variation. Alcohol is the most 
common cause in western countries (122) and liver disease is the 5th most common cause of 
death in the United Kingdom (123.) Recent reports on pre-clinical and clinical studies 
suggested that LC could be reversible. HSCs activated upon liver injury are thought to be 
responsible for collagenogenesis and fibrosis in extracelluar matrix (124, 125). Modulation of 
HSC activity (126.), promotion of HSC apoptosis (127), blocking of matrix formation (128) or 
anti-proliferation measures on matrix fibrogenic and contractile response to HSC and 
degradation of established matrix (125,129) could be taken as potent strategies for reversal of 
LC. In addition to these strategies, stem cell therapy with multiple cytokine production and 
trans-differentiation potential would be a new option (130) for reversal of established LC.  
HSCs are responsible for the production of extracellular matrix at the center of LC. 
Therefore, the inhibition of the activation of HSCs (131-133) or promotion of HSC apoptosis 
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(134-135) would be an eradicating measure for fibrogenesis. The platelet-derived growth 
factor (PDGF) is the most potent mitogen for HSCs, thereby inhibitors against PDGF have 
been tried (136-138). For the patients whose fibrosis is progressing, the matrix formation 
blockers (139) or anti-proliferation measures to matrix fibrogenesis (140) would be another 
measure for the reduction of LC. HSCs contribute to portal hypertension through multiple 
mechanisms including collagen deposition, vasoconstriction, and regulation of sinusoidal 
structure. So, the reduction of contractile response to HSC (141) would be a measure 
reducing critical complications induced by portal hypertension. Increasing the degradation 
of established matrix (125,142,142) would be an ideal strategy for reversal of LC.  
Recently developed stem cell therapy (143-144) may be a promising strategy for LC, because 
we can expect them to trans-differentiate into hepatocytes and to stimulate the 
differentiation of hepatocytes from the dormant stem cells remaining in injured host liver 
and stem cells in bone marrow through cytokine production (145). BMSC, ADSC, and 
UCBSC are currently used for stem cells therapy. Unseparated bone marrow cells and 
purified BMSCs have been used for the treatment of the hematopoietic diseases for more 
than 50 years. Their application fields are expanding day by day. For advanced liver 
diseases such as cirrhosis, stem cell engraftment can be most promising strategy after the 
organ transplantation (146). In animals treated with CCl4 intraperitoneal infusion, the 
percentage of lin- Sca-1+ cells in the bone marrow and peripheral blood increases twofold at 
twenty-four hours later (147) and this increase peaks at day one in the bone marrow and day 
two in the peripheral blood (147). This finding suggests that bone stem cells started to 
proliferate and migrate to the periphery (147). Requirement of engraftment of stem cells into 
the patients with the severe liver diseases are increasing. For BMSC therapy, bone marrow 
aspiration is inevitable and bone marrow aspiration is a invasive procedure. Differentiation 
potential, and maximal life span of BMSC decrease with increasing age (148-149). In post-
hepatitic LC patients, the autologous BMSCs are not suitable for the treatment, because their 
proliferation capacity is restricted significantly in the tissue environment of end stage of the 
disease (150) 
ADSCs were relatively recently found. Their easy isolation (151) and high differentiation 
potential (152) may be attractive as alternative promising stem cells in place of BMSCs. In 
the meantime, UCBSCs has been used for several diseases.  UCBSCs have advantages over 
other types of stem cells, because umbilical cord blood (UCB) can be obtained without 
invasiveness or harm to donor. Cells from UCB have many advantages because of the 
immaturity of stem cells compared to other types. Moreover, UCBSCs provide no ethical 
barriers for basic and clinical applications (153-154). Recently, UCB banking for 
transplantation of haematopoietic stem cells is increasingly in many institutions (155) due to 
their easy availability and the ready on shelf system. All clinical papers are of autologous or 
allogenic stem cell therapy. Among the adult stem cells, UCBSCs are youngest stem cells 
and they had only few chances to contact with environmental antigens. UCBSCs have 
higher proliferative potential than BMSC and higher expression of the endothelial-specific 
markers following endothelial differentiation (156). 
When we decided to attempt to treat with UCBSCs for some diseases, we carefully consider 
suitable cell (origin) for target organs, cell numbers, route for administration, 
supplementation of growth factors and post-treatment cares. In spite of increasing 
requirement of stem cell treatment, the protocol for stem cell treatment has not established 
until now. Because the preparation of the stem cells for enough quantity that has the 
identical or similar biology is not easy, we should consider the measure to secure the 
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enough number of stem cells, culture or mixing of different donors. Although many trials 
with stem cell were done, most of them are autologous rather than allogenic. Basically, 
many diseases caused by different pathogenesis, it needs different treatment. In case of LC, 
bone marrow stem cells from liver cirrhotic caused by chronic hepatitis B infection showed 
significantly lower S-phase fractions and growth factor (IGF-1, PDGF ǂ, PDGF ǃ) receptor 
expression than normal people (157). It indicates that allogenic stem cell therapy is better 
than autologous in LC. We suppose that allogenic stem cell therapy would be reasonable in 
case of the hereditary or genetic disease. The number of stem cells in specific treatment has 
not decided yet, too. Moriya et al. (158) used 1x105 embryonal stem cells in animal study 
model (mice). Liu et al.(159) used 5x105 endothelial precusor cells in 150 g animal study 
model(rat). Yan et al. (160) infuse 3x106 hunman UCBSCs in mice. Although these reports 
are animal study, when we calculate the cell number in weight to weight (animal to human) 
base, the cell number for human treatment should be over 1x108 cells. But Mohamadnejad et 
al. (161) infused 31.73 x 106 autologous bone marrow mesenchymal stem cells for four liver 
cirrhotic patients via peripheral vein. So, the cell number for treatment of disease should be 
standardized according to the disease, although there should be many trials for 
standardization.  
In introduction part of this chapter, we mentioned on the characteristics of stem cells, 
homing or migration (someone uses ‘targeting’). Homing in stem cell biology means stem 
cell moving toward injury site along the some chemotactic signal (162). So, many animal 
experiments localized the targeted stem cells, which were infused via tail vein (260-164) or 
intraperitoneal infusion(165) and sometimes via specific route such as portal vein(166). And 
in case of cellular cardioplasty for myocardiac infarction model, several different infusion 
has been used, direct intracoronary (167), intravenous with homing(168) and mobilization 
with homing from bone marrow or peripheral blood(169). In cellular cardiomyoplasty, 
according to the cell delivery system, the results are different. Least effective method is 
mobilization from peripheral blood or bone marrow(170-171) and most effective method is 
intracoronary infusion (172-173). And in case of intravenous infusion, according to the blood 
flow, all blood in body has to pass the lung and some proportion of infused stem cells are 
trapped at the lung (174-175). Some are trapped at other organs(176).  
There are many growth factors which support or enhancing stem cell activities. The 
supplement of growth factors into stem cell culture media or coupled treatment of stem cell 
with growth factors was reported in vitro and in vivo, already. Supplement of growth 
factors in culture system has been done from long ago in culturing technique and sometimes 
essential job for culture, but the coupled clinical treatment of stem cell with growth factors 
(177-178) are in different conditions (177-178). Although we use the various growth factors 
for in vitro culture system, there are a few growth factors which are permitted to use for 
human from the health concerning governmental bureau. So, it is not easy to search the 
simultaneous application of the growth factor as an auxiliary measure for stem cell therapy 
(178-180). 
Post-treatment care are difficult to mention at present time because there is no report for 
large sized world wide data related on the stem cell treatment on specific disease until now. 
Although the data on the post-treatment care for better maintenance of end result of stem 
cell therapy are needed, it is not proposed yet. As in the material and method, we had the 
clinical treatment for end-stage LC whose survival was expected to be less than 6 months. 
The result showed that the all patients had improved survival although their initial life 
expectancy was based on the doctor's experiences. Other laboratory data had some 
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differences among patient to patient, but most of the patients who had the hepatic 
encephalopathy and more than half of the ascitic patient had the improved symptoms.  
In author's stem cell treatment for LC, we used umbilical cord blood stem cells (UCBSCs), 
only. UCBSCs produce and secrete various humoral factors (cytokine or growth 
factors)(261-262). They are stem cell factor (SCF), macrophage colony stimulating factor (M-
CSF), granulocyte macrophage colony stimulating factor (GM-CSF), vascular endothelial 
growth factor (VEGF), interleukin 1ǃ (IL-1ǃ), IL-6, IL-8, IL-11, IL-12, IL-15, stromal cell-
derived factor 1ǂ (SDF-1ǂ), hepatocyte growth factor (HGF), epitehlial cell-derived protein 
78 (ENA-78), Growth-related oncogene (GRO), oncostain M (OSM), monocyte 
chemoattractant protein-1 (MCP-1), fibroblast growth factor 4 (FGF-4), FGF-7, FGF-9, 
granulocyte chemotactic protein 2 (GCP-2), Insulin like growth factor (IGF), Insulin-like 
growth factor binding protein 1 (IGFBP-1), IGFBP-2, IGFBP-3, IGFBP-4, Interferon-gamma-
inducible protein 10 (IP-10), Leukemia inhibitory factor (LIF), migration inhibitory factor 
(MIF), macrophage inflammatory protein 3ǂ (MIP-3alpha), osteoprotegerin, (OPG), 
pulmonary and activation-regulated chemokine (PARC), Placenta growth factor (PIGF), 
transforming growth factor ǃ1(TGF-ǃ1), TGF-ǃ2, TGF-ǃ3, tissue inhibitors of matrix 
metalloproteinases 1 (TIMP-1) and TIMP-2.  
Among these cytokines, some of them are favorable for antifibrosis and some are prone to 
enhance the fibrosis in liver. The results of balance between favorable and unfavorable 
effects among the various cytokines secreted from the UCBSC would predict treatment or 
aggravation of LC. Among above cytokines that UCBSCs secrete, HGF, IGF-1, IGFBP and 
interferon would be closely related with fibrolysis of liver but TGF-ǃ1 and TIMP will 
promote hepatic fibrosis. Although the results of UCBSC treatment on LC patient showed 
much improvement on symptoms and liver function related laboratory data, we do not 
know the interaction between those cytokines, which has some antagonistic effects.  
We injected stem cells into liver parenchyme directly under the ultrasound guide. Total cell 
numbers were around 1.5 x 107 hUCBSCs in each patient. Until now, there are many trials 
with animal model of LC but no author has presented the proper cell number for stem cell 
treatment on LC. Around 1 x 106 cells were infused intravascularly in rat or mouse liver 
cirrhosis model and they showed improvement in hepatic functions. Although the most of 
patients in our treatment group showed favorable effects on LC after stem cell therapy, the 
role of cell number in LC treatment was not definite. We infused the stem cells directly into 
the target organ, liver, the cell number that authors used were much less than animal 
experiments. In spite of our small numbered stem cells, there was some improvement in 
data for hepatic function.  
As mentioned before, we infused the stem cells directly into the liver parenchyma. The 
infusion route would be closely related with results of the stem cell treatment. In systemic 
intravenous administration would be the easiest method in stem cell treatment but the 
trapping of stem cell by lung or some reticuloendothelial system, during circulation before 
homing, would lessen the treatment effects. Although there are several data related with 
homing after intravenous infusion of stem cells, it is unclear that how many portions of 
infused cells are homed. To increase the homed stem cells in target organ, some therapies 
try to infuse the stem cells via selective artery, although it is invasive. More invasive therapy 
would be the orthotopic infusion/transplantation of stem cells under direct of indirect 
visualization. Surgically exposed target lesion would be treated with high accuracy and 
possibly permit reduced numbered stem cell implantation with same effects. Modern 
developed imaging modalities enabled us target the lesions with very high accuracy with 
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less damage. The choice of the route for best effective targeting the lesion would be depend 
on the imaging modality and technique of operator. 
Average life expectancy of the LC patients chose randomly by authors is expected to no 
more than 6 months. After stem cell therapy, no body had gone within 6 month and two of 
51 patients survived more than 5 years. There would be many causes contributing to the 
improvement of patients' survival. Among them, the role of stem cell for improvement of 
survival and laboratory data should get attention. Although Kögler and Liu reported the 
various cytokines, which they detected from UCBSCs, there would be many unknown 
cytokines (humoral factors), which is secreted by the UCBSCs. We do not know the 
mechanisms that improved survival and laboratory data in liver function, but the HGF, INF 
and IGF and IGFBP would be closely related with fibrolysis and collagenolysis.  
Originally HGF has mitogenic, motogenic, morphogenic and anti-cell death activities (181), 
and identified and cloned as a mitogen protein for hepatocyte (182-183). HGF stimulates 
expression and activity of proteases involved in breakdown of ECM proteins, including 
urokinase-type plasminogen activator and matrix metalloproteinases. In LC, HGF suppress 
the proliferation while promoting apoptosis of ǂ-SMA-positive cells in the liver, that 
histological resolution from liver cirrhosis.(181) Growth inhibition and promotion of 
apoptosis in portal myofibroblasts by HGF would be an ancillary resolution for liver 
fibrosis/cirrhosis.(184) Mesenchymal stem cells (MSCs) can prevent the development of 
liver fibrosis, and hepatocyte growth factor (HGF) can also attenuate liver cirrhosis. (185) 
HGF/MSCs significantly inhibit the formation of liver fibrosis in rats, while MSCs and HGF 
had synergistic effects in the process. The antifibrosis effect of HGF/MSCs may have 
contributed in modulating the activation and apoptosis of HSCs, elevating the rHGF 
expression level, and decreasing the TGF-beta 1 secretion of activated HSCs.(185). In CCl4-
induced liver cirrhosis rat model, hBMSCs treatment results were induced by two 
mechanisms that work together: the differentiation of transplanted hBMSCs into liver cells 
that are able to restore normal liver functions, and expression by production of MMP by 
hBMSCs which is involved in the repair of liver fibrosis. (186). 
In interferon, there are many subtypes but only a few of them are reported to be produced 
from the UCBSCs. Among them, interferon alpha (IFN-ǂ) suppress the progression of 
hepatic fibrosis (187), and lowers fibrosis scores, tissue hydroxyproline levels, liver TIMP-1 
and elevate MMP-13 levels. IFN-ǂ has role to increases HSC apoptosis, too(188). TIMP is the 
representative fibrosis favoring molecule and MMP is the representative molecule for 
fibrolysis. IFNǄ have the hepatic protective effect by inhibition of adenosine A2A receptor 
function in hepatic stellate cells (191). Among those cytokines, M-CSF promotes the 
interferone production. 
Insulin-like growth factor-1 (IGF-1) and major portion of the circulating IGF-1 synthesized 
in the liver are hepatic origin in normal state, but in LC the plasma levels are diminished 
(190-191). When the deficient IGF-1 in LC was replaced by daily administration of 
recombinant IGF-1, it induces a significant improvement of liver function (192). In liver, the 
expression of IGF-1 receptor is poor (193-194) and it seems that IGF-I acts on 
nonparenchymal cells. IGF-1 improves the liver structures and function through the 
activation of tissue-repair mechanism at non-parenchyma. It seems that there is an 
amplification loop which are favoring the efficacy of the therapy because the IGF-1 
upregulate the IGF-1R in hepatic septa (195). In liver cirrhosis, the supplementation of IGF-1 
induces the antifibrogenic and hepatoprotective effects. (196) Aside from the antifibrogenic 
effects, patients treated with stem cell showed improved serum albumin and enzyme levels 
indicating liver functions and these results are supposed due to IGF effects.  
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This discussion reviewed the mechanism that stem cell have favoring results related with 
LC. But it would not be the total mechanisms that explain the favoring effect of stem cells on 
LC. Among the above mentioned cytokines produced by UCBSCs, there are reports for 
characterization of cytokins, such as SDF-1(197) IL-8 (198) M-CSF (199), RANTES (200), MIP-
1ǂ (201), IP-10 (202) and EGF (203), but the most of them are not directly related with 
improvement of LC.  
Until now, there are several clinical papers, around 10, on the results of autologous stem cell 
treatments, either autologous bone marrow derived stem cells or mobilized stem cells and fetal 
stem cell for the end stage liver cirrhotic patients. All of them are backing further clinical 
application of stem cell on liver cirrhosis. Most of the reports were related with the treatment 
with small number of patients, less than 10 patients, except for India (204). And the routes of 
stem cell infusion, aside from the mobilized hepatopoietic stem cells, are portal vein or hepatic 
artery with a few intravenous infusions. With these data, it is practically difficult to compare 
the superiority of the route of stem cell infusion due to small patient number in each case. 
Although there are common findings are improvement of hepatic conditions.  
In the clinical data that we introduced in this chapter, all patients were supposed to be gone 
within 6 months before they were involved in stem cell therapy, meaning terminal state LC 
patients. Two third in 51 had the ascitis and more than one third had the hepatic 
encephalopathy. After single stem cell therapy using UCBSC, most of the hepatic 
encephalopathy patients and more than two third of ascitic patients were improved in 
symptom or responded to medical therapy who were refractory to previous therapy. But other 
data for liver function, albumin, aminotransferases, bilirubin or prothrombin time has 
irregular responses. About half of patients of ascites who had the improved symptoms 
showed improved albumin values but difficult to pull out any reproducible protocol, requiring 
further study. Because we choose the patients randomly in loose exclusion criteria, it would be 
difficult to get the objectively reproducible data from our experience for base of any protocol 
in stem cell therapy. But we can get some idea of trends of stem cell therapy for LC, although 
we had a single treatment. The stem cell therapy improves the ascitis and hepatic 
encephalopathy definitely in some group of patient, although we do not characterized this 
group, yet. In case of hepatic encephalopathy, the most of patients showed objectively 
improved symptom but we do not presume the mechanism, too. At the point of patient 
survival, all patients survived more than 6 months, although it would be difficult to believe the 
patients’ initial life expectancy as the objective data. The patients' survival would not be 
related with liver function only but would be the summation of the various indexes of life 
signs. The most common side reaction that related with the stem cell treatment was pain, 
experiencing during stem cell infusion procedures. As mentioned before, much of the stem cell 
biology including producing cytokines has been proven already but it would be a tip of 
iceberg. We treated the patients who were regarded as the hopeless condition in point of 
survival improvement based on the reasonable solid animal study results of stem cell therapy, 
but they lack objective clinical efficacy aside from trend of stem cell therapy. So, to get the 
further acquisition of objective clinical effects and base on proper protocol, large multicenter 
trial on stem cell therapy for liver cirrhosis would be needed. 
5. Conclusion 
The conclusion of our review and experience is that there are lots of beneficial effects of stem 
cells on end stage liver cirrhosis and stem cell therapy serves for prolongation of the life and 
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improvement of quality of life. The analysis of author’s experience lacks objectivity. And if 
there is the more systemic multicenter large numbered study, we can make the proper 
guideline for stem cell therapy on liver cirrhosis. 
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